{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:27:32Z","timestamp":1789637252893,"version":"4.0.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK R01 029953"],"award-info":[{"award-number":["DK R01 029953"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.mayocp.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T10:06:24Z","timestamp":1662026784000},"page":"1700-1716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-9422","authenticated-orcid":false,"given":"Rita","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-0092","authenticated-orcid":false,"given":"Jeanne M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib4","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib5","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.31599","article-title":"NAFLD: reporting histologic findings in clinical practice","volume":"73","author":"Brunt","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib6","first-page":"83","article-title":"Diagnostic and treatment implications of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"15","author":"Wong","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.mayocp.2022.04.005_bib9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"Mottillo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity\u2014a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.mayocp.2022.04.005_bib11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017\u2014Part 1: definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017\u2014Part 2: management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions","volume":"49","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.mayocp.2022.04.005_bib18","series-title":"Non-alcoholic fatty liver disease (NAFLD): assessment and management","year":"2016"},{"issue":"30","key":"10.1016\/j.mayocp.2022.04.005_bib19","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in NAFLD\u2014revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.mayocp.2022.04.005_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr Hepatol Rep"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0261-5614(99)80015-6","article-title":"Non-alcoholic fatty liver: another feature of the metabolic syndrome?","volume":"18","author":"Cortez-Pinto","year":"1999","journal-title":"Clin Nutr"},{"issue":"8","key":"10.1016\/j.mayocp.2022.04.005_bib25","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2022.04.005_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.14360","article-title":"The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management","volume":"40","author":"Berna","year":"2020","journal-title":"Liver Int"},{"issue":"22","key":"10.1016\/j.mayocp.2022.04.005_bib27","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.3390\/ijms21228761","article-title":"Nutrients, genetic factors, and their interaction in non-alcoholic fatty liver disease and cardiovascular disease","volume":"21","author":"Lombardi","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.mayocp.2022.04.005_bib28","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mayocp.2022.04.005_bib29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A\u00a0protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.mayocp.2022.04.005_bib31","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.mayocp.2022.04.005_bib32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.mayocp.2022.04.005_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120933804","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease phenotypes","volume":"8","author":"Bisaccia","year":"2020","journal-title":"SAGE Open Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2022.04.005_bib35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.mayocp.2022.04.005_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40842-020-00097-1","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: where do diabetologists stand?","volume":"6","author":"Tomah","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.mayocp.2022.04.005_bib37","author":"Hales"},{"issue":"25","key":"10.1016\/j.mayocp.2022.04.005_bib38","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi","year":"2019","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib42","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.mayocp.2022.04.005_bib43","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1001\/archinte.164.19.2169","article-title":"Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults","volume":"164","author":"Kim","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib45","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","article-title":"The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States Population","volume":"51","author":"Jinjuvadia","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"39","key":"10.1016\/j.mayocp.2022.04.005_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.mayocp.2022.04.005_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mayocp.2022.04.005_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.mayocp.2022.04.005_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.mayocp.2022.04.005_bib52","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2022.04.005_bib53","first-page":"467","article-title":"NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations","volume":"10","author":"Niederseer","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib54","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib55","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.amjmed.2020.01.007","article-title":"Nonalcoholic fatty liver disease: what does the primary care physician need to know?","volume":"133","author":"Budd","year":"2020","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2022.04.005_bib57","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"1124","key":"10.1016\/j.mayocp.2022.04.005_bib58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison","year":"2019","journal-title":"Postgrad Med J"},{"issue":"10","key":"10.1016\/j.mayocp.2022.04.005_bib59","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib60","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib61","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib62","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.31655","article-title":"Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD","volume":"73","author":"Cassinotto","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.mayocp.2022.04.005_bib63","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","article-title":"Current status of imaging in nonalcoholic fatty liver disease","volume":"10","author":"Li","year":"2018","journal-title":"World J Hepatol"},{"issue":"7","key":"10.1016\/j.mayocp.2022.04.005_bib64","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3748\/wjg.v27.i7.609","article-title":"Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort","volume":"27","author":"Imajo","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib65","doi-asserted-by":"crossref","first-page":"15308","DOI":"10.1038\/s41598-020-71995-8","article-title":"A\u00a0composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis","volume":"10","author":"Dennis","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/apt.14469","article-title":"Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease","volume":"47","author":"Eddowes","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib67","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cld.2017.08.006","article-title":"The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom","volume":"22","author":"Gunn","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib69","doi-asserted-by":"crossref","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","article-title":"Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations","volume":"116","author":"Younossi","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mayocp.2022.04.005_bib70","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","volume":"50","author":"Ajmera","year":"2021","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib71","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib72","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib73","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2022.04.005_bib74","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/apt.15830","article-title":"Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices","volume":"52","author":"Younossi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib75","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.mayocp.2022.04.005_bib76","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.mayocp.2022.04.005_bib77","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","article-title":"ESPEN practical guideline: clinical nutrition in liver disease","volume":"39","author":"Bischoff","year":"2020","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib78","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cld.918","article-title":"Nutrition management strategies for nonalcoholic fatty liver disease: treatment and prevention","volume":"15","author":"Miller","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib79","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1210\/jc.2016-3722","article-title":"Randomized controlled trial of a MUFA or fiber-rich diet on hepatic fat in prediabetes","volume":"102","author":"Errazuriz","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.mayocp.2022.04.005_bib80","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mayocp.2022.04.005_bib81","doi-asserted-by":"crossref","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.mayocp.2022.04.005_bib82","series-title":"Costs and outcomes of increasing access to bariatric surgery for obesity: cohort study and cost-effectiveness analysis using electronic health records","author":"Gulliford","year":"2016"},{"issue":"8","key":"10.1016\/j.mayocp.2022.04.005_bib83","article-title":"Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: recommendation statement","volume":"99","year":"2019","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000496183","article-title":"European practical and patient-centred guidelines for adult obesity management in primary care","volume":"12","author":"Durrer Schutz","year":"2019","journal-title":"Obes Facts"},{"issue":"suppl 3","key":"10.1016\/j.mayocp.2022.04.005_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.mayocp.2022.04.005_bib86","author":"Karam"},{"issue":"12","key":"10.1016\/j.mayocp.2022.04.005_bib87","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2022.04.005_bib90","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antiox7010012","article-title":"Vitamin E as a treatment for nonalcoholic fatty liver disease: reality or myth?","volume":"7","author":"El Hadi","year":"2018","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s13643-019-1200-8","article-title":"Diabetes drugs for nonalcoholic fatty liver disease: a systematic review","volume":"8","author":"Blazina","year":"2019","journal-title":"Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib93","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/dom.13592","article-title":"Of mice and men: is there a future for metformin in the treatment of hepatic steatosis?","volume":"21","author":"Green","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib95","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib96","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.mayocp.2022.04.005_bib97","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.mayocp.2022.04.005_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.163","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): a systematic review","volume":"3","author":"Lv","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"10019","key":"10.1016\/j.mayocp.2022.04.005_bib99","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib100","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001956","article-title":"SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews","volume":"8","author":"Shao","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2022.04.005_bib105","first-page":"S125","article-title":"10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"10295","key":"10.1016\/j.mayocp.2022.04.005_bib106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib107","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib108","first-page":"72","article-title":"Efficacy and safety of drugs for nonalcoholic steatohepatitis","volume":"22","author":"Shen","year":"2021","journal-title":"J\u00a0Dig Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2022.04.005_bib109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/phar.2489","article-title":"Emerging therapies for the treatment of non-alcoholic steatohepatitis: a systematic review","volume":"41","author":"Guirguis","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.mayocp.2022.04.005_bib110","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"issue":"10215","key":"10.1016\/j.mayocp.2022.04.005_bib117","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2022.04.005_bib118","first-page":"1447A","volume":"68","author":"Ratziu","year":"2018","journal-title":"Hepatology"},{"issue":"10213","key":"10.1016\/j.mayocp.2022.04.005_bib119","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2022.04.005_bib120","author":"Higgins-Dunn"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/cd21-as01","article-title":"Standards of Medical Care in Diabetes\u20142021 abridged for primary care providers","volume":"39","year":"2021","journal-title":"Clin Diabetes"},{"issue":"11","key":"10.1016\/j.mayocp.2022.04.005_bib122","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib123","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"33","key":"10.1016\/j.mayocp.2022.04.005_bib124","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib125","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.mayocp.2022.04.005_bib126","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"Authors\/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.mayocp.2022.04.005_bib127","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm\u20142020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"4S","key":"10.1016\/j.mayocp.2022.04.005_bib128","first-page":"S1","article-title":"KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.mayocp.2022.04.005_bib129","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2022.04.005_bib130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease\u2014from pathophysiology to clinical effects","volume":"11","author":"Laursen","year":"2019","journal-title":"World J Hepatol"},{"issue":"12","key":"10.1016\/j.mayocp.2022.04.005_bib131","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.04.005_bib132","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mayocp.2022.04.005_bib133","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.04.005_bib134","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2019.07.026","article-title":"Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease","volume":"71","author":"Abu Dayyeh","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.mayocp.2022.04.005_bib135","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.gie.2020.08.023","article-title":"Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty","volume":"93","author":"Hajifathalian","year":"2021","journal-title":"Gastrointest Endosc"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622002440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622002440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T20:36:25Z","timestamp":1713990985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622002440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":124,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0025619622002440"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.04.005","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}